User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 05:50, 6 October 2021 (diff | hist) . . (+99) . . 1.3.5 Reward system and incentives (→C. Resources)
- 05:47, 6 October 2021 (diff | hist) . . (+98) . . 1.4.1.2 Data sharing (→C. Resources) (current)
- 05:39, 6 October 2021 (diff | hist) . . (+39) . . 1.4.1.2 Data sharing (→C. Resources)
- 05:38, 6 October 2021 (diff | hist) . . (+68) . . 1.4.1.2 Data sharing
- 05:36, 6 October 2021 (diff | hist) . . (+87) . . 1.4.1.2 Data sharing (→C. Resources)
- 07:43, 14 September 2021 (diff | hist) . . (0) . . 2.1.6 Sample size and power analysis (→C. Resources) (current)
- 12:29, 13 August 2021 (diff | hist) . . (+402) . . Spot checks
- 12:24, 13 August 2021 (diff | hist) . . (+57) . . Spot checks
- 12:23, 13 August 2021 (diff | hist) . . (0) . . Spot checks
- 12:23, 13 August 2021 (diff | hist) . . (-29) . . Spot checks
- 12:13, 13 August 2021 (diff | hist) . . (+942) . . N Spot checks (Created page with "For a spot check, data / experiments may be selected randomly to see how well the RU is doing by finding answers to questions like ‘how easy is it to retrieve and reconstruc...")
- 12:12, 13 August 2021 (diff | hist) . . (+4) . . 4.1.2 Self assessment (current)
- 09:18, 15 July 2021 (diff | hist) . . (+828) . . N EQIPD:About (Created page with "To support robustness and reliability of preclinical biomedical research in a collaborative manner, the Enhancing Quality in Preclinical Data (EQIPD; originally called Europea...") (current)
- 09:50, 14 June 2021 (diff | hist) . . (+45) . . 1.4.3.3 Academia-academia: Research as service (→Background)
- 09:48, 14 June 2021 (diff | hist) . . (-9) . . 1.4.3.3 Academia-academia: Research as service
- 09:47, 14 June 2021 (diff | hist) . . (-9) . . 1.4.3.3 Academia-academia: Research as service (→Proposed recommendations)
- 09:46, 14 June 2021 (diff | hist) . . (+6) . . 1.4.3.2 Industry-academia: Research as collaboration (current)
- 09:45, 14 June 2021 (diff | hist) . . (+50) . . 1.4.3.1 Industry-academia: Research as service (→Background and Expectations)
- 17:55, 10 May 2021 (diff | hist) . . (+1) . . Core Requirements (current)
- 17:21, 10 May 2021 (diff | hist) . . (-17) . . Glossary
- 14:49, 10 May 2021 (diff | hist) . . (0) . . 3.2.3 Implementation of the EQIPD Quality System (→Take a closer look at the expectations of EQIPD)
- 08:49, 6 May 2021 (diff | hist) . . (+326) . . Documentation in EQIPD (current)
- 08:46, 6 May 2021 (diff | hist) . . (+1) . . Documentation in EQIPD
- 08:41, 6 May 2021 (diff | hist) . . (+1) . . Core Requirements
- 08:40, 6 May 2021 (diff | hist) . . (+101) . . Core Requirements
- 08:39, 6 May 2021 (diff | hist) . . (+127) . . Core Requirements
- 08:38, 6 May 2021 (diff | hist) . . (-38) . . Core Requirements (Undo revision 18809 by Antonbespalov (talk)) (Tag: Undo)
- 08:37, 6 May 2021 (diff | hist) . . (+39) . . Core Requirements (Undo revision 18810 by Antonbespalov (talk)) (Tag: Undo)
- 08:36, 6 May 2021 (diff | hist) . . (-39) . . Core Requirements
- 08:36, 6 May 2021 (diff | hist) . . (+38) . . Core Requirements
- 08:32, 6 May 2021 (diff | hist) . . (-10) . . 1.4.2 Adherence to legal and regulatory considerations (→B. Guidance & Expectations)
- 08:31, 6 May 2021 (diff | hist) . . (+2) . . 1.4.2 Adherence to legal and regulatory considerations (→B. Guidance & Expectations)
- 08:30, 6 May 2021 (diff | hist) . . (-1) . . 1.4.2 Adherence to legal and regulatory considerations (→B. Guidance & Expectations)
- 08:30, 6 May 2021 (diff | hist) . . (+1) . . 1.4.2 Adherence to legal and regulatory considerations (→B. Guidance & Expectations)
- 08:30, 6 May 2021 (diff | hist) . . (+315) . . 1.4.2 Adherence to legal and regulatory considerations (→B. Guidance & Expectations)
- 05:14, 31 March 2021 (diff | hist) . . (-2) . . 3.2.3 Implementation of the EQIPD Quality System
- 05:13, 31 March 2021 (diff | hist) . . (-233) . . 3.2.3 Implementation of the EQIPD Quality System
- 06:15, 30 March 2021 (diff | hist) . . (+28) . . Glossary
- 06:13, 30 March 2021 (diff | hist) . . (+176) . . Glossary
- 11:23, 29 March 2021 (diff | hist) . . (+118) . . Glossary
- 06:49, 25 March 2021 (diff | hist) . . (+69) . . 1.4.3.2 Industry-academia: Research as collaboration (→Background)
- 06:48, 25 March 2021 (diff | hist) . . (+181) . . 1.4.3.2 Industry-academia: Research as collaboration (→Background)
- 06:46, 25 March 2021 (diff | hist) . . (+22) . . 1.4.3.2 Industry-academia: Research as collaboration (→Expectations)
- 06:44, 25 March 2021 (diff | hist) . . (+3,543) . . 1.4.3.2 Industry-academia: Research as collaboration (→Expectations)
- 06:42, 25 March 2021 (diff | hist) . . (+16) . . 1.4.3.2 Industry-academia: Research as collaboration (→Background)
- 06:42, 25 March 2021 (diff | hist) . . (+1,334) . . 1.4.3.2 Industry-academia: Research as collaboration (→Background and Expectations)
- 06:40, 25 March 2021 (diff | hist) . . (-20) . . 1.4.3.2 Industry-academia: Research as collaboration (→C. Resources)
- 06:40, 25 March 2021 (diff | hist) . . (+191) . . 1.4.3.2 Industry-academia: Research as collaboration (→Resources)
- 06:38, 25 March 2021 (diff | hist) . . (-3) . . 1.4.3 Quality in collaborative research (→C. Resources) (current)
- 13:32, 17 March 2021 (diff | hist) . . (+1,587) . . N 1.4.3.1 Industry-academia: Research as service (Created page with "=Background and Expectations= A significant percentage of drug discovery and development efforts is outsourced to external service providers. Biopharmaceutical industry aims...")
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
